Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Hematology

Screening Your Family Members

At a Glance

Routine testing of every relative is usually not recommended for inherited Protein C deficiency. Testing is most useful when a result could change decisions about estrogen-containing hormones, pregnancy-related clot prevention, or another major care choice.

Because Protein C deficiency is an inherited condition, it is natural to wonder if your parents, siblings, or children should also be tested. However, medical guidelines have moved away from “testing everyone” [1][2]. Instead, the goal is selective screening: testing only when the result will directly change a person’s medical care [3][4].

Conditional Guidelines on Family Screening

The American Society of Hematology (ASH) provides guidance on when to test asymptomatic relatives (family members who have never had a blood clot). Their recommendations are conditional and often based on very low-certainty evidence, but they generally recommend against routine, universal screening of all relatives just because a family member has a deficiency [1][2].

Instead, testing is conditionally recommended only in specific scenarios where the result helps a person make a major health decision [1]:

  • Hormonal Decisions: To help a woman decide whether to avoid estrogen-containing birth control or hormone replacement therapy [5][6].
  • Pregnancy Planning: To determine if a woman needs preventive blood thinners during pregnancy or the six weeks after birth [7][8].
  • (Note: Testing to guide contraception or pregnancy decisions is not the same as testing before every surgery, flight, or minor procedure, and a positive result does not automatically determine prophylaxis for those events [2][9].)

Why Not Test Everyone?

It may seem like “more information is always better,” but testing people who have no symptoms can have several downsides:

  1. Incomplete Penetrance: Having the mutation does not mean a person will ever develop a clot. A positive test result can cause significant anxiety for a “problem” that may never actually happen [10][11].
  2. False Reassurance or Alarm: Testing during an illness or while taking certain medications can produce misleading results. A “false positive” might lead to unnecessary lifelong medication, while a “false negative” might lead a person to ignore real symptoms [12][13].
  3. Insurance and Labeling: In some regions or situations, a documented genetic “deficiency” can affect a person’s ability to get certain types of life or disability insurance, even if they are perfectly healthy [5][14].
  4. Testing Minors: Protein C levels are naturally low in newborns and young children, so testing minors needs age-specific interpretation and is often deferred unless it will change care.

Decision Aid: How Family Testing Works

If a relative decides to proceed with testing, there are two main ways to do it:

Testing Method When to Use It Important Considerations
Targeted Genetic Testing When your specific familial pathogenic variant is already known. This is the most accurate way to see if they inherited the condition, and it isn’t affected by their current health or medications [15][16]. However, a negative test for the family variant does not eliminate ordinary acquired VTE risks.
Functional Activity Assays When the genetic variant is unknown, or to see how the protein is actually performing. CRITICAL: Relatives must NEVER discontinue anticoagulation solely for testing. DOACs, heparin, warfarin, acute illness, pregnancy, and liver disease can all affect interpretation. The hematologist and laboratory should choose the assay [17][18].

The Role of Genetic Counseling

Before testing family members, it is often helpful to meet with a genetic counselor. They can help your family understand the difference between a relative with a known familial pathogenic variant versus a general family history, navigate the emotional implications, and ensure the right tests are ordered [19][20].

Common questions in this guide

Should everyone in a family be tested for Protein C deficiency?
Usually not. Selective testing is considered when the result could change an important decision, such as using estrogen-containing birth control or hormone therapy, planning pregnancy, or deciding about preventive blood thinners after birth.
Which relatives are usually considered for testing?
Parents, siblings, and children are first-degree relatives who may be discussed with a hematologist or genetic counselor. Testing is not automatically needed for all of them; timing and priority depend on whether the result would change their care.
Is a genetic test or a Protein C activity test better?
If the family’s specific disease-causing gene change is known, a targeted genetic test is usually the most accurate way to determine whether a relative inherited it, and medicines or illness do not change that result. If the gene change is unknown, a Protein C activity test may be considered, but a clinician and laboratory must interpret it because medicines, illness, pregnancy, and liver disease can affect the result.
Can I stop a blood thinner before Protein C testing?
No one should stop anticoagulation solely to obtain testing unless the treating clinician specifically directs it. Blood thinners, including direct oral anticoagulants, heparin, and warfarin, can affect some activity tests, so the hematologist and laboratory should choose the safest approach.
Does a positive Protein C deficiency test mean a relative will develop a blood clot?
No. The deficiency can increase the chance of a clot, but many people with the inherited change never develop one; a positive result does not automatically mean lifelong medication or preventive treatment before every surgery or flight.
Should children be tested for Protein C deficiency?
Testing in newborns and young children can be difficult to interpret because Protein C levels are naturally low at those ages. A pediatric or hematology specialist may recommend waiting unless testing would change medical care.
How can genetic counseling help before family testing?
A genetic counselor can explain what a family-specific gene test or activity test can and cannot show, discuss emotional and insurance concerns, and help make sure the right test is ordered. They can also help relatives consider how a result might affect pregnancy or hormone decisions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my Protein C deficiency, which of my first-degree relatives (parents, siblings, children) should be prioritized for testing?
  2. 2.If my sister is planning a pregnancy or considering birth control, is a Protein C activity test enough, or should she have a targeted genetic test for my specific mutation?
  3. 3.How would a positive result for an asymptomatic family member change how you manage them during a minor surgery or a long-distance flight?
  4. 4.Are there specific labs or genetic counselors you recommend who specialize in inherited thrombophilias to ensure the results are interpreted correctly?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.

    Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al.

    Blood advances 2023; (7(22)):7101-7138 doi:10.1182/bloodadvances.2023010177.

    PMID: 37195076
  2. 2

    Guidance for the evaluation and treatment of hereditary and acquired thrombophilia.

    Stevens SM, Woller SC, Bauer KA, et al.

    Journal of thrombosis and thrombolysis 2016; (41(1)):154-64 doi:10.1007/s11239-015-1316-1.

    PMID: 26780744
  3. 3

    Inherited thrombophilias: Genetics and testing considerations.

    Tinkle MB

    Journal of the American Association of Nurse Practitioners 2026; (38(1)):2-7 doi:10.1097/JXX.0000000000001216.

    PMID: 41481204
  4. 4

    Clinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: A 5-Year retrospective study.

    Munda E, Rhoades R

    Journal of thrombosis and thrombolysis 2026; (59(2)):462-471 doi:10.1007/s11239-025-03183-2.

    PMID: 41047446
  5. 5

    Re-Examining Genetic Screening and Oral Contraceptives: A Patient-Centered Review.

    Hiedemann B, Vernon E, Bowie BH

    Journal of personalized medicine 2019; (9(1)) doi:10.3390/jpm9010004.

    PMID: 30650548
  6. 6

    Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.

    van Vlijmen EF, Wiewel-Verschueren S, Monster TB, Meijer K

    Journal of thrombosis and haemostasis : JTH 2016; (14(7)):1393-403 doi:10.1111/jth.13349.

    PMID: 27121914
  7. 7

    Inherited Thrombophilia and Pregnancy Complications: Should We Test?

    Arachchillage DRJ, Makris M

    Seminars in thrombosis and hemostasis 2019; (45(1)):50-60 doi:10.1055/s-0038-1657782.

    PMID: 29864774
  8. 8

    Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis.

    Croles FN, Nasserinejad K, Duvekot JJ, et al.

    BMJ (Clinical research ed.) 2017; (359()):j4452 doi:10.1136/bmj.j4452.

    PMID: 29074563
  9. 9

    Perioperative management of severe congenital protein C deficiency.

    Watanabe K, Kato M, Ishimaru T, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(8)):646-649 doi:10.1097/MBC.0000000000000654.

    PMID: 28737523
  10. 10

    Analysis of PROC mutations and clinical features in 22 unrelated families with inherited protein C deficiency.

    Xu F, Zhang K, Xu Q, et al.

    Annals of hematology 2024; (103(2)):645-652 doi:10.1007/s00277-023-05487-w.

    PMID: 37950050
  11. 11

    Thrombophilia evaluation in pulmonary embolism.

    Stern RM, Al-Samkari H, Connors JM

    Current opinion in cardiology 2019; (34(6)):603-609 doi:10.1097/HCO.0000000000000668.

    PMID: 31389825
  12. 12

    A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management.

    Gavva C, Sarode R, Zia A

    Blood advances 2017; (1(25)):2386-2391 doi:10.1182/bloodadvances.2017009514.

    PMID: 29296888
  13. 13

    An Audit of Thrombophilia Testing in Patients with Ischemic Stroke or Transient Ischemic Attack: The Futility of Testing.

    Gavva C, Johnson M, De Simone N, Sarode R

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018; (27(11)):3301-3305 doi:10.1016/j.jstrokecerebrovasdis.2018.07.032.

    PMID: 30143267
  14. 14

    Appropriateness of thrombophilia testing in patients in the acute care setting and an evaluation of the associated costs.

    Virparia R, Brunetti L, Vigdor S, Adams CD

    Journal of thrombosis and thrombolysis 2020; (49(1)):108-112 doi:10.1007/s11239-019-01930-w.

    PMID: 31388853
  15. 15

    Molecular characterization of novel splice site mutation causing protein C deficiency.

    Al-Hamed MH, AlBatniji F, AlDakheel GA, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016; (27(5)):585-8 doi:10.1097/MBC.0000000000000490.

    PMID: 26656900
  16. 16

    Laboratory Limitations of Excluding Hereditary Protein C Deficiency by Chromogenic Assay: Discrepancies of Phenotype and Genotype.

    Seidel H, Haracska B, Naumann J, et al.

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2020; (26()):1076029620912028 doi:10.1177/1076029620912028.

    PMID: 32309994
  17. 17

    Protein C Deficiency.

    Dinarvand P, Moser KA

    Archives of pathology & laboratory medicine 2019; (143(10)):1281-1285 doi:10.5858/arpa.2017-0403-RS.

    PMID: 30702334
  18. 18

    Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

    Khider L, Gendron N, Mauge L

    International journal of molecular sciences 2022; (23(3)) doi:10.3390/ijms23031821.

    PMID: 35163742
  19. 19

    Prenatal genetic testing for familial severe congenital protein C deficiency.

    Tairaku S, Taniguchi-Ikeda M, Okazaki Y, et al.

    Human genome variation 2015; (2()):15017 doi:10.1038/hgv.2015.17.

    PMID: 27081530
  20. 20

    Protein C Deficiency Caused by a Novel Mutation in the PROC Gene in an Infant with Delayed Onset Purpura Fulminans.

    Al Harbi MS, El-Hattab AW

    Case reports in dermatological medicine 2017; (2017()):8915608 doi:10.1155/2017/8915608.

    PMID: 29082047

This page explains family screening for inherited Protein C deficiency for informational purposes only and does not constitute medical advice. A hematologist or genetic counselor should interpret results and advise your family about pregnancy, hormones, and clot prevention.

Get notified when new evidence is published on thrombophilia due to protein C deficiency, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.